Despite Maravai LifeSciences Holdings' significant liabilities, it has net cash, indicating a light debt load. However, its pre-interest and tax loss and declining revenue raise future earnings and balance sheet health concerns.
While Maravai LifeSciences Holdings displays a low ROE, its ability to expand net income considerably due to efficient management and high profit reinvestment is a positive sign. Current analyst forecasts suggest continued earnings growth for the company.
While Maravai LifeSciences Holdings displays a low ROE, its ability to expand net income considerably due to efficient management and high profit reinvestment is a positive sign. Current analyst forecasts suggest continued earnings growth for the company.
While Maravai LifeSciences Holdings displays a low ROE, its ability to expand net income considerably due to efficient management and high profit reinvestment is a positive sign. Current analyst forecasts suggest continued earnings growth for the company.
While Maravai LifeSciences Holdings displays a low ROE, its ability to expand net income considerably due to efficient management and high profit reinvestment is a positive sign. Current analyst forecasts suggest continued earnings growth for the company.
Analysts project a revenue dip and a reduced price target for Maravai LifeSciences Holdings. Increased investor caution may apply due to expected underperformance.
MoffettNathanson Upgrades$Zoom视频通讯(ZM.US)$to Market Perform From Underperform, Price Target Is $85 Zoom Video Communications has an average rating of hold and price targets ranging from $65 to $105, according to analysts polled by Capital IQ. HSBC Upgrades$雪佛龙(CVX.US)$to Buy From Hold, Price Target Is $189 Chevron (CVX) has an average rating of outperform and price targets ranging from $161 to $212, according to ...
Maravai LifeSciences股票讨论区
Maravai LifeSciences Holdings, Inc.(代码:MRVI)是一家领先的生命科学公司,提供关键产品以支持药物治疗、诊断和新型疫苗的开发,并支持人类疾病的研究。公司在核酸合成和生物安全检测两大领域优势突出。
1
落难的公主
2022年2月25日,彭博社报道称,Sartorius AG(赛多利斯)提出以 110亿美元收购Maravai LifeSciences(MRVI)。
赛多利斯是业界赫赫有名的一家通过持续收购不断做大做强的生命科学集团公司。这个出价必然是深思熟虑的。当时MRVI董事会认为,这个出价严重低估了公司价值,故而拒绝了赛多利斯的并购请求。时过境迁,此后MRVI的市值一路下跌,时至今日已经不足10亿美元。
MRVI还有未来吗?
2
产品线
1、核酸合成业务线(Nucleic Acid Production,NAP)
提供高度修饰和复杂的核酸以及相关酶用于分子诊断、疫苗和治疗等领域。
清洁盖帽技术(CleanCap®)是公司在mR...
新增数据:2022Q4及全年,2023前两季度
2022Q4营收下滑10.4%,营业利润下滑29.3%,净利润下滑31.2%,这使得2022年营收增长10.5%,营业利润仅增长4.2%,净利润仅增长4.6%。
2023前两季度营收持续下滑,造成了连续4个季度下滑,营业利润在2季度亏损,净利润则在两个季度均亏损,这使得上半年营收下滑69.6%,营业利润转为亏损,净利润亏损0.13亿。
目前市盈率6.2,市盈率TTM已经提高到17.5,目前没有任何趋势扭转的迹象,平仓了结。
Zoom Video Communications has an average rating of hold and price targets ranging from $65 to $105, according to analysts polled by Capital IQ.
HSBC Upgrades $雪佛龙(CVX.US)$ to Buy From Hold, Price Target Is $189
Chevron (CVX) has an average rating of outperform and price targets ranging from $161 to $212, according to ...
4年来营收、营业利润和净利润都保持高速增长,2022前三季度营收增长19%,营业利润增长16.5%,净利润增长17.6%,增速有所下滑,但是依然还在增长。
近4年资产负债率从73%上升到88%后下降到了72%。
资产负债表显示公司流动资产大幅增长达到8.4亿,长期借款5.3亿,占净资产的63%,杠杆率居中。
5年来现金流经营净额大幅超越投资净额,股东盈余很多。
目前市盈率8.9,市盈率TTM 7.7,可以选择(⭐️⭐️)
暂无评论